BMJ Pre Submission Checklist: Clinical Practice Readiness

1. Will this finding change how clinicians manage patients?

BMJ's threshold is the same as NEJM's: practice-changing evidence. But BMJ has a specific advantage for research that is international in scope. If your study draws on non-US populations, addresses global health questions, or comes from a non-US institution, BMJ is meaningfully more receptive than NEJM or JAMA.

2. Is the clinical question relevant to BMJ's general medical readership?

BMJ publishes across all of clinical medicine. A study that matters only within one narrow specialty (interventional cardiology, neuro-oncology) may be better suited to a specialty journal. The question is whether a general internist, family physician, or public health professional would find the result directly relevant to their practice.

3. Does the abstract make the practice implication concrete?

BMJ editors scan abstracts quickly. If the practice-changing finding is buried after two paragraphs of methods description, the first impression is weaker. Lead with the clinical question and the answer.

4. Is the study design appropriate for the clinical claims?

BMJ favors randomized trials, large cohort studies, systematic reviews, and health services research. Observational studies are published but face higher scrutiny. The key question: is the design strong enough that a clinician would change their practice based on these results?

5. Are the statistical methods rigorous enough for independent review?

BMJ sends papers to independent statistical reviewers. Like NEJM and JAMA, the statistical review evaluates sample size justification, analytical methods, missing data handling, and multiplicity corrections. Prepare for questions your clinical reviewers would not ask.

6. Does the paper have international applicability?

This is where BMJ differs most from NEJM and JAMA. BMJ has a genuinely international editorial perspective. Research relevant to healthcare systems in multiple countries, studies from low- and middle-income settings, and work addressing global health challenges receive priority consideration. If your study is US-only, you need to explain why the findings apply internationally.

7. Is the paper framed for an international clinical audience?

Drug names, clinical pathways, and healthcare system references that are specific to one country should be contextualized. US brand names should include generic names. UK-specific NHS terminology should be explained for international readers.

8. Is the reporting checklist complete?

CONSORT for trials (2025 update if applicable), STROBE for observational, PRISMA for systematic reviews. BMJ published the CONSORT 2025 statement alongside JAMA, The Lancet, Nature Medicine, and PLOS Medicine. Complete the checklist with specific page references.

9. Are ethics approvals, trial registration, and data sharing documented?

Trial registration is required before enrollment. Ethics approval must be stated with institution and approval number. BMJ requires a data sharing statement. The journal offers a subscription track with no APC (articles free after 6 months, immediate free access in low-income countries), which satisfies many funder open access mandates.

BMJ enforces the EQUATOR-network reporting guidelines as a hard desk-screen item, and an incomplete or missing checklist is one common way to lose a strong paper before review. Match the guideline to the study design and complete it with specific page references:

• CONSORT 2025 for randomized controlled trials. BMJ co-published the CONSORT 2025 update alongside JAMA, The Lancet, Nature Medicine, and PLOS Medicine, so the current version is expected.

• STROBE for observational studies (cohort, case-control, cross-sectional).

• PRISMA for systematic reviews and meta-analyses, with the protocol registered on PROSPERO where applicable.

• SPIRIT for trial protocols and CHEERS for economic evaluations.

A checklist that points each item to "see Methods" without a page number is treated the same as a missing checklist at triage. Complete it against the final manuscript, not the draft, so the page references stay accurate after revision.

10. Does the cover letter explain clinical impact concisely?

BMJ editors may reject at the first editorial screen if they are convinced the journal is not the right fit. The cover letter is one of the first fit signals they read. Keep it short: state the finding, the clinical implication, and why BMJ specifically is the right journal. Do not spend a paragraph on background.

If the paper addresses an ongoing public health emergency or has immediate policy implications, flag this explicitly in the cover letter. BMJ has a fast-track process for time-sensitive public health research.

BMJ uses open peer review, meaning reviewer names are published alongside the accepted paper. This creates a different review dynamic than journals with anonymous review: reviewers tend to be more constructive and less arbitrarily harsh, but they also expect higher methodological rigor because their reputation is attached. BMJ also requires data sharing statements and encourages or requires raw data deposit. These transparency requirements should be addressed before submission, not retrofitted during revision.

Check your BMJ readiness automatically. The Manusights free scan evaluates your manuscript against BMJ's editorial standards in about two to three minutes.

For a paper targeting BMJ, the BMJ submission readiness check provides citation-risk checks, figure-level feedback, and journal-specific calibration. For career-defining submissions, Manusights Expert Review connects you with reviewers who have published in and reviewed for BMJ.

• No practice change. The clinical finding does not change practice for general physicians.

• Too specialty-specific. The study is too narrow for a general medical journal.

• Unclear international relevance. The applicability is uncertain, especially for single-country studies.

• Design undermines the claim. The study design has limitations that undercut the clinical claims.

• Buried practice implication. The abstract does not state the practice implication in the first three sentences.

• Format or length violation. The paper exceeds the word limit or does not match the required format.

• Unregistered or retrospective trial. The trial is not registered, or registration was retrospective.

For more detail, see BMJ Under Review: Status Meanings and the BMJ Submission Guide.

For manuscripts targeting BMJ, the problem is usually not basic compliance. It is framing for a general clinical audience without losing methodological precision. Three patterns recur across the submissions we screen before they reach the BMJ portal.

The specialist abstract. We often see strong health-services or specialty studies that are rigorous enough for BMJ but written as if the reader already works in that niche. The abstract names a finding that matters to one subspecialty, and the practice implication for a general internist or family physician is left implicit. BMJ editors screen the general clinical consequence first, so the abstract has to make the practice change obvious in the first three sentences, not after two paragraphs of methods.

The single-system result. A second pattern is a study whose data, drug names, and care pathways are specific to one country's healthcare system, with no explanation of why a clinician elsewhere should care now. For BMJ specifically, the submission needs to contextualize brand names with generics, explain system-specific terminology, and state the international applicability directly rather than leaving the reviewer to infer it.

The compliance gap discovered late. The third pattern is a methodologically sound paper whose reporting checklist, trial registration, or data-sharing statement is incomplete at submission. These are mechanical items the desk screen checks before reading the results: the CONSORT, STROBE, or PRISMA checklist with page references, the registration number in the abstract, the ethics approval and data-availability statement in the methods. A revision should close these before upload, not during peer review.

The papers that travel best at BMJ make the practice implication obvious early and explain why the result matters beyond one healthcare system, usually by adding one direct sentence to the abstract and cover letter rather than more background, and by closing every reporting and registration item before the submission is uploaded.

BMJ's editorial-team page is worth checking before you quote or address any named editor in a cover letter. That staffing context matters because this is not a faceless upload queue: BMJ editors usually screen the general clinical consequence before they reward polished formatting. The checklist matters most when it supports that page-one case instead of burying it under procedural compliance.